ALS Ltd (ASX: ALQ) Share Price and News
Price
$16.88
Movement
0.02 (+0.12%)
as at 16 Jun - Closed (20 mins delayed)
52 Week Range
$13.09 - $18.19
1 Year Return
+19.55%
ALS Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
$16.88
Day Change
0.02 (+0.12%)
52 Week Range
$13.09 - $18.19
Yesterday's Close
$16.86
Today's Open
$16.78
Days Range
$16.71 - $16.96
Volume
949,243
Avg. Volume (1 month)
1,446,189
Turnover
$16,014,736
as at 16 Jun - Closed
ALS Ltd (ASX: ALQ)
Latest News

Broker Notes
Brokers name 3 ASX shares to buy today

Broker Notes
Why Macquarie expects this ASX 200 dividend stock to keep outperforming

Share Fallers
Why ALS, Black Cat, Boss Energy, and Soul Patts shares are falling today

Broker Notes
Guess which ASX 200 share Goldman Sachs just downgraded

Share Fallers
Why ALS, Fisher & Paykel Healthcare, IPD, and Predictive Discovery shares are falling today

Industrials Shares
Key takeaways from ALS shares results according to Macquarie

52-Week Highs
5 ASX 200 shares smashing new 52-week highs today

52-Week Highs
5 ASX 200 shares hitting multi-year highs after strongly rebounding from tariff turmoil

Share Gainers
Here are the top 10 ASX 200 shares today

Broker Notes
Leading brokers name 3 ASX shares to buy today

Share Gainers
Why ALS, Life360, Nuix, and Sovereign Metals shares are pushing higher today

Broker Notes
Top broker says this ASX 200 share is a buy for a 10%+ return
Frequently Asked Questions
-
Yes, ALS Ltd historically pays two partially or fully franked dividends a year.
-
ALS Ltd generally pays its shareholder dividends in July and December
-
ALS Ltd listed on the ASX on 18 July 1952.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
27 Nov 2024 | $0.1890 | 30.00% | Interim | 19 Dec 2024 |
12 Jun 2024 | $0.1960 | 20.00% | Final | 02 Jul 2024 |
23 Nov 2023 | $0.1960 | 20.00% | Interim | 14 Dec 2023 |
09 Jun 2023 | $0.1940 | 10.00% | Final | 06 Jul 2023 |
24 Nov 2022 | $0.2030 | 0.00% | Interim | 16 Dec 2022 |
06 Jun 2022 | $0.1700 | 30.00% | Final | 04 Jul 2022 |
02 Dec 2021 | $0.1580 | 30.00% | Interim | 17 Dec 2021 |
07 Jun 2021 | $0.1460 | 70.00% | Final | 05 Jul 2021 |
26 Nov 2020 | $0.0850 | 100.00% | Interim | 16 Dec 2020 |
05 Jun 2020 | $0.0610 | 70.00% | Final | 06 Jul 2020 |
27 Nov 2019 | $0.1150 | 30.00% | Interim | 16 Dec 2019 |
03 Jun 2019 | $0.1150 | 35.04% | Final | 01 Jul 2019 |
29 Nov 2018 | $0.1100 | 20.00% | Interim | 18 Dec 2018 |
06 Jun 2018 | $0.0900 | 40.00% | Final | 02 Jul 2018 |
29 Nov 2017 | $0.0800 | 40.00% | Interim | 18 Dec 2017 |
07 Jun 2017 | $0.0000 | 0.00% | Final | 03 Jul 2017 |
05 Dec 2016 | $0.0550 | 60.00% | Interim | 21 Dec 2016 |
08 Jun 2016 | $0.0600 | 40.00% | Final | 01 Jul 2016 |
03 Dec 2015 | $0.0750 | 25.07% | Interim | 18 Dec 2015 |
11 Jun 2014 | $0.2000 | 50.00% | Final | 02 Jul 2014 |
07 Jun 2013 | $0.2700 | 50.00% | Final | 02 Jul 2013 |
05 Jun 2009 | $0.4250 | 0.00% | Final | 01 Jul 2009 |
01 Dec 2008 | $0.4250 | 58.82% | Interim | 17 Dec 2008 |
06 Jun 2008 | $0.5100 | 58.82% | Final | 01 Jul 2008 |
30 Nov 2007 | $0.2975 | 58.82% | Interim | 17 Dec 2007 |
06 Jun 2007 | $0.3570 | 58.82% | Final | 02 Jul 2007 |
29 Nov 2006 | $0.2380 | 58.82% | Interim | 15 Dec 2006 |
05 Jun 2006 | $0.2900 | 100.00% | Final | 03 Jul 2006 |
25 Nov 2005 | $0.2100 | 100.00% | Interim | 20 Dec 2005 |
04 Jun 2004 | $0.1900 | 100.00% | Final | 01 Jul 2004 |
28 Nov 2003 | $0.1400 | 100.00% | Interim | 19 Dec 2003 |
ALQ ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|
About ALS Ltd
ALS Ltd (ASX: ALQ) is one of the world's largest laboratory testing, inspection, certification, and verification businesses. It operates from around 350 sites across 65 countries.
Listed on the ASX in 1952, ALS operates three divisions: commodities, life sciences, and industrial. ALS's commodities segment traditionally generates the majority of the company's underlying earnings. It provides geochemistry, metallurgy, inspection, and mine site services for the mining industry globally.
The company also provides environmental, pharmaceutical, and food and beverage testing and certification. ALS Ltd has a multi-billion dollar market capitalisation and is part of the ASX 100.
ALQ Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
13 Jun 2025 | $16.86 | $0.24 | 1.44% | 1,063,494 | $16.64 | $16.91 | $16.64 |
12 Jun 2025 | $16.62 | $-0.08 | -0.48% | 1,279,857 | $16.68 | $16.78 | $16.45 |
11 Jun 2025 | $16.70 | $0.00 | 0.00% | 1,211,470 | $16.89 | $16.99 | $16.68 |
10 Jun 2025 | $16.70 | $0.25 | 1.52% | 1,323,745 | $16.53 | $16.86 | $16.47 |
06 Jun 2025 | $16.45 | $0.01 | 0.06% | 870,007 | $16.41 | $16.62 | $16.32 |
05 Jun 2025 | $16.44 | $0.24 | 1.48% | 1,461,232 | $16.26 | $16.58 | $16.22 |
04 Jun 2025 | $16.20 | $0.12 | 0.75% | 1,372,919 | $16.14 | $16.43 | $16.06 |
03 Jun 2025 | $16.08 | $0.03 | 0.19% | 1,559,362 | $16.11 | $16.19 | $15.97 |
02 Jun 2025 | $16.05 | $-0.02 | -0.12% | 1,384,583 | $16.07 | $16.22 | $15.97 |
30 May 2025 | $16.07 | $-0.15 | -0.92% | 1,892,680 | $16.11 | $16.24 | $16.00 |
29 May 2025 | $16.22 | $-0.08 | -0.49% | 3,497,725 | $16.20 | $16.55 | $16.03 |
28 May 2025 | $16.30 | $-1.34 | -7.60% | 4,795,327 | $16.50 | $16.59 | $16.00 |
26 May 2025 | $17.64 | $-0.05 | -0.28% | 1,096,864 | $17.71 | $17.75 | $17.48 |
23 May 2025 | $17.69 | $-0.05 | -0.28% | 946,787 | $17.35 | $17.71 | $17.22 |
22 May 2025 | $17.74 | $-0.11 | -0.62% | 905,067 | $17.58 | $17.95 | $17.48 |
21 May 2025 | $17.85 | $0.03 | 0.17% | 968,855 | $17.93 | $17.93 | $17.62 |
20 May 2025 | $17.82 | $0.11 | 0.62% | 1,179,673 | $17.72 | $17.94 | $17.58 |
19 May 2025 | $17.71 | $-0.16 | -0.90% | 1,034,819 | $17.71 | $17.85 | $17.62 |
16 May 2025 | $17.87 | $0.13 | 0.73% | 1,079,318 | $17.91 | $18.01 | $17.63 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
25 Nov 2024 | Peter Possemiers | Buy | 3,100 | $50,902 |
On-market trade.
|
20 Nov 2024 | Nigel Garrard | Buy | 3,950 | $60,049 |
On-market trade.
|
08 Aug 2024 | Nigel Garrard | Buy | 2,250 | $33,412 |
On-market trade.
|
31 Jul 2024 | Malcom Deane | Issued | 163,082 | $2,304,360 |
Issue of securities. 398,893 Rights
|
01 Jul 2024 | Malcom Deane | Expiry | 424 | $5,952 |
As advised by the company. 257,297 - Performance Rights
424 Performance Rights forfeited |
01 Jul 2024 | Malcom Deane | Exercise | 21,486 | $301,663 |
Conversion of securities. 2,35,811 - Performance Rights & Service Rights
|
01 Jul 2024 | Malcom Deane | Issued | 18,088 | $253,955 |
Issue of securities. 257,721 - Performance Rights
As per announcement on 04/07/2024. |
01 Jul 2024 | Malcom Deane | Buy | 21,486 | $301,663 |
Conversion of securities.
|
28 Jun 2024 | Nigel Garrard | Buy | 2,750 | $39,595 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Nigel David Garrard | Non-Executive Deputy ChairmanNon-Executive Director | Jun 2023 |
Mr Garrard is an executive with a record across the fast-moving consumer goods and industrial/manufacturing sectors. He has over 20 years of experience as an ASX-listed CEO across three companies. In 2019, he retired as Managing Director and CEO of Orora Limited. He led the demerger of Orora Limited from Amcor, and the subsequent listing of Orora Limited on ASX in 2013. He was President of the Amcor Australasia and Packaging Distribution business group, Managing Director of Coca-Cola Amatil's Food and Services Division, and Managing Director of SPC Ardmona. Nigel brings international experience across listed, not-for-profit, government and private entities. He is currently the Chairman of Ansell Limited, Chairman of Flinders Port Holdings Pty Ltd, Chairman of the McMahon Services advisory board, and Director of Treasury Wine Estates Limited.
|
Dr John Francis Mulcahy | Non-Executive Director | Feb 2012 |
Mr Mulcahy is Chairman of Orix Australia Corporation Limited, an unlisted public company (appointed March 2016). He is also a current Non-Executive Director of various Zurich Australia Insurance subsidiaries and GWA Group Limited. John was previously a director and Chairman of both Mirvac Group Limited (November 2009 - December 2022), Coffey International Limited (September 2009 - January 2016). He is a former Guardian of the Future Fund of Australia and former Managing Director and Chief Executive Officer of Suncorp-Metway Limited. Prior to Suncorp, John held several senior executive roles at the Commonwealth Bank and Lend Lease Corporation. He is a member of the Sustainability and Innovation Committee.
|
Ms Tonianne Dwyer | Non-Executive Director | Jul 2016 |
Ms Dwyer has experience as a company director and executive working in finance, corporate strategy and mergers and acquisitions across a variety of sectors and international markets. She is an internationally experienced independent company director, having had a 25-year executive career in investment banking during which she held roles with Hambros Bank Limited and Societe General in the UK and Europe. Tonianne currently holds a non-executive directorship role with Dyno Nobel, Growthpoint Properties Australia and AUB Group. Her previous roles included non-executive director positions with OZ Minerals Limited, DEXUS Property Group, DEXUS Wholesale Property Fund, Metcash Limited, Queensland Treasury Corporation and Cardno Limited. She is a member of the People Committee and Risk Committee.
|
Ms Leslie A Desjardins | Non-Executive Director | Nov 2019 |
Ms Desjardins has a background as a CFO and senior financial and governance professional in a range of large multinational and global businesses. She has commercial and financial governance expertise with large multinational public companies in North America, Canada, and Australia each with global operations. Her areas of expertise include CFO level executive and financial strategic leadership, M&A, corporate finance and treasury, governance, financial and tax compliance, and enterprise risk management. Leslie is currently a Director, Audit Committee Chair, Human Resource Committee member with Ansell Limited. During her executive career, Leslie served as Executive VP and CFO at Amcor Limited, a global leader in packaging of food, beverage, pharmaceutical and tobacco products. Prior to Amcor Ltd, Leslie served in financial and corporate strategic positions with General Motors Corporation, including Chief Financial Officer GM Holden Australia, Controller GM North America, Executive Director Manufacturing Finance and Director GM North America Strategy and Planning. She is the Chair of the Risk Committee and from April 2025 a member of the People Committee. In FY25, Leslie was a member of the Sustainability and Innovation Committee.
|
Dr Siddhartha Kadia | Non-Executive Director | Jan 2019 |
Mr Kadia is currently CEO and Director at Calibre Scientific, a privately held company that services life sciences tools industry. Siddhartha has lived and worked in the US, Japan, China, and India and has more than 20 years of international experience as a company director, executive and technical leader in the Life Sciences and TIC (testing, inspection and certification) sectors. Siddhartha was formerly President and CEO of EAG Laboratories, a global scientific testing company headquartered in San Diego, California. He has also been a Director of USA-listed companies Newport Corporation (NSDQ: NEWP), Volcano Corporation (NSDQ: VOLC), Isoplexis Corporation (NSDQ:ISO), Berkeley Lights (NDSQ:BLI), Horizon Discovery Group (LSW:HZD), Nuvasive, Inc (NSDQ: NUVA). Siddhartha was also a management consultant at McKinsey & Company where his work focused on various life sciences and healthcare related engagements. He is the Chair of the Sustainability and Innovation Committee, a member of the People Committee.
|
Ms Erica Mann | Non-Executive Director | Mar 2024 |
Ms Mann is a C-suite executive with a 30- year career across complex, highly regulated, multi-channel and multi-product environment in top DAX, NYSE, NSDAQ pharmaceutical, OTC and FMCG multinationals. Before retiring as an executive, Erica led Bayer's Consumer Health Division, one of the world's largest OTC companies with 6 billion euro in turnover. Prior to joining Bayer, she was President and General Manager of Pfizer Nutrition following its acquisition of Wyeth Inc, where she served as Senior Vice President of Global Nutrition. This followed the other senior executive roles of other Fortune 500 companies including Eli-Lily and Johnson & Johnson. She has held leadership positions in South Africa, Australia, New Zealand, Germany, Switzerland and the US. In addition to her executive experience in the nutrition and health industry, Erica has experience with global and emerging markets across Africa, China, Russia, and Brazil. Erica currently serves as an independent director of Kenvue, DSM-Firmenich and Kellogg where she is a member of the Audit, and Social Responsibility & Public Policy Committees. She is a member of the Sustainability and Innovation Committee.
|
Mr Peter Possemiers | Non-Executive Director | Nov 2022 |
Mr Possemiers has a background as a TIC sector expert with almost 40 years of experience working as a senior executive in leadership roles globally for SGS. He has lead teams both regionally and globally most notably SGS's global Environment Health and Safety business, then a CHF 550 million business with a global headcount which exceeded 6000. As Executive Vice President, he was a member of the SGS Operations Council with responsibility for the strategic growth and profitability of the business, leading 15 strategic acquisitions. He moved into management roles in Singapore, Philippines, China and Korea, where he established and developed new markets including food, pharma, and mobile technology. In 2013, Peter was promoted to Executive Vice President, Global Environment, Health & Safety, a position based in Switzerland which he held for 8 years before moving into his most recent role as Vice President, Strategic Integration in 2021 following the acquisition of the Synlab A&S business, which covered the environmental, food, pharma and oil condition monitoring testing sector across Europe. He is the Chair of the People Committee, and a member of the Risk Committee.
|
Mr Malcom Deane | Chief Strategy Officer General Manager Life Sciences - Food & Pharma Americas GeneralChief Executive OfficerManaging Director | Mar 2023 |
Mr Deane has served the company in various executive positions for the past 10 years in such roles as General Manager for Life Sciences Latin America, Food & Pharma Americas, and most recently as the Chief Strategy Officer, leading corporate strategy, business development and acquisitions.
|
Ms Catharine Farrow | Non-Executive Director | Mar 2025 |
Dr Farrow is a director of Franco-Nevada and has more than 30 years of mining industry experience in all aspects of exploration, development, technical services, acquisitions, company building, operations, board governance and innovation/technology. Her experience ranges from the High Arctic to equatorial environments in base, critical and precious metals. Catharine Farrow also serves as a director of Eldorado Gold Corporation, is lead director of Aclara Resources Inc., and until November 2024, was on the Board of Centamin PLC. She is also active in the mining and technology industries in both public and private companies, and academia as President of FarExGeoMine Ltd., where she provides advisory support in technical, governance, innovation and technology, organizational structure and as an expert witness. Previously she had been COO of KGHM International and held various other executive roles in precursor companies from 2003 to 2012 including as Chief Technology Officer and Senior Vice President Corporate Development and Technical Services (including joint ventures, M&A opportunities, and strategy). She is a member of the Sustainability and Innovation Committee.
|
Mr Michael Paul Pearson | Company Secretary | Dec 2017 |
-
|
Ms Dayna Field | Company SecretaryGeneral Counsel | Oct 2024 |
-
|
Stuart Hutton | Chief Financial Officer |
-
|
|
Michael Paul Pearson | Company Secretary |
-
|
|
Dayna Field | Company SecretaryGeneral Counsel |
-
|
|
Tim Kilmister | GM Environmental |
-
|
|
Andreas Jonsson | GM Food & Pharma |
-
|
|
Bruce McDonald | GM Geochemistry |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
No Top 20 Shareholder | 0 | 0.00% |